Armistice Capital, LLC Reports New 9.99% Passive Stake in Artelo Biosciences, Inc. (ARTL)

On May 15, 2026, Armistice Capital, LLC and Steven Boyd filed a Schedule 13G disclosing a new 9.99% ownership stake in Artelo Biosciences, Inc. (ARTL). The reporting persons beneficially own 235,823 shares of common stock as of the event date on March 31, 2026. Armistice Capital, LLC serves as the investment manager to Armistice Capital Master Fund Ltd., which is the direct holder of the shares. Steven Boyd, as the managing member of Armistice Capital, LLC, may also be deemed to have shared voting and dispositive power over these securities. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. This position represents a significant new holding for the investment firm, moving from a previously reported 0% ownership to nearly 10% of the company's outstanding common stock.